SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Launched by SUN YAT-SEN UNIVERSITY · Sep 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with advanced laryngeal or hypopharyngeal cancer. The treatment combines a type of targeted radiation therapy called SBRT with a combination of chemotherapy and immunotherapy drugs (specifically Toripalimab, Docetaxel, and Cisplatin). The goal is to see if this combination can safely help preserve the larynx (voice box) while effectively treating the cancer.
To be eligible for this trial, participants need to be between 18 and 70 years old and have specific types of laryngeal or hypopharyngeal cancer. They should also be in good overall health, able to tolerate chemotherapy and immunotherapy, and not have other serious cancers or conditions that would prevent them from participating. If chosen to take part, participants can expect to receive the new treatment and be closely monitored for safety and effectiveness. This trial is currently looking for volunteers, so it’s a great opportunity for those who meet the criteria to contribute to important cancer research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
- • age 18-70
- • PS score 0-1
- • normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
- Exclusion Criteria:
- • Patients with a combination of other malignant tumours
- • Individuals with contraindications to immunotherapy
About Sun Yat Sen University
Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported